OnCo
companiesCompany

CARsgen Therapeutics

CARsgen Therapeutics developed satri-cel, the first CAR-T approved for a solid tumour (gastric cancer, China).

Satricabtagene autoleucel (CLDN18.2), zevor-cel (BCMA, China), allogeneic and GPC3 programmes.

Headquarters
Shanghai, CN
Type
cell therapy · 2171.HK

Products

1top
Under reviewCAR-T (Claudin 18.2)
Satricabtagene autoleucel

Satricabtagene autoleucel (satri-cel) is the first CAR-T therapy approved for a solid tumour (gastric cancer), in China.

Connected

6top

cancers

2
Gastric & gastro-oesophageal junction cancerPancreatic ductal adenocarcinoma

fronts

1
Cell Therapy

drugs

1
Under reviewCAR-T (Claudin 18.2)
Satricabtagene autoleucel

institutions

1
Peking University Cancer Hospital

people

1
Lin Shen